Training for the Oral Administration of Sodium Iodide I-131 in Quantities Greater than 1.22

Gigabequerels (33 millicurie) for Which a Written Directive Is Required Except as provided in 105 CMR 120.528, the licensee shall require an authorized user for the oral administration of sodium iodide I-131 in quantities greater than 1.22 gigabecquerels (33 millicuries), for which a written directive is required, to be a physician who: (A) Is certified by a medical specialty board whose certification process includes all of the requirements in 105 CMR 120.558(C)(1) and (2) and whose certification has been recognized by the Agency, an Agreement State or the Nuclear Regulatory Commission. The names of board certifications that have been recognized by the Agency, Nuclear Regulatory Commission or an Agreement State are posted on the NRC's Medical Uses License Toolkit Web page; or (B) Is an authorized user under 105 CMR 120.556, for uses listed in 105 CMR 120.556(B)(1)(b)6.b. or equivalent Agreement State, or Nuclear Regulatory Commission requirements; or (C)(1) Has successfully completed 80 hours classroom and laboratory training, applicable to the medical use of sodium iodide I-131 for procedures requiring a written directive. The training must include: (a) Radiation physics and instrumentation; (b) Radiation protection; (c) Mathematics pertaining to the use and measurement of radioactivity; (d) Chemistry of radioactive material for medical use; and, (e) Radiation biology; and, (2) Has work experience, under the supervision of an authorized user who meets the requirements in 105 CMR 120.528, 120.556, or 120.558, or equivalent Agreement State, or Nuclear Regulatory Commission requirements. A supervising authorized user who meets the requirements of 105 CMR 120.556(B), must also have experience in administering dosages as specified in 105 CMR 120.556(B)(1)(b)6.b.; the work experience must involve: (a) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys; (b) Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters; (c) Calculating, measuring, and safely preparing patient or human research subject dosages; (d) Using administrative controls to prevent a medical event involving the use of byproduct material; (e) Using procedures to contain spilled radioactive material safely and using proper decontamination procedures; and (f) Administering dosages to patients or human research subjects that includes at least three cases involving the oral administration greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131; and (3) Has obtained written attestation that the individual has satisfactorily completed the requirements in 105 CMR 120.558(C)(1) and (2), and is able to independently fulfill the radiation safety-related duties as an authorized user for oral administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I–131 for medical uses authorized under 105 CMR 120.552. The attestation must be obtained from either: (a) A preceptor authorized user who meets the requirements in 105 CMR 120.528, 120.556, 120.558, or equivalent Nuclear Regulatory Commission or Agreement State requirements, and has experience in administering dosages as specified in 105 CMR 120.556(B)(1)(b)6.b.; or (b) A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in 105 CMR 120.528, 120.556, 120.558, or equivalent Nuclear Regulatory Commission or Agreement State requirements, has experience in administering dosages as specified in 105 CMR 120.556(B)(1)(b)6.b., and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in 105 CMR 120.558(C)(1) and (2).